Fig. 5
From: Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy
(Adapted with permission from [80]. Copyright © 2021 The Authors. Published by American Chemical Society)
Organic porous nanomaterials for tumor immunotherapy. A Construction and characterization of three-dimensional (3D) covalent organic frameworks (COFs). B Time-resolved PL spectra of COF-607 to COF-609. C Steady-state PL spectra contrast of COF-607 to COF-609. D ROS production efficiency of COF-607, COF-608, and COF-609 compared to PCN-224. E Quantification of immune cells in the draining lymph nodes, CD3+ T cells (E) and CD4+ CD25+ Foxp3+ Treg cells (F). G Quantification of CD11b+ Ly6g+ MDSCs in the spleen. H Time schedule of the establishment of bilateral tumor mouse model and treatments. I, J Growth curves of primary and distant tumors of bilateral 4T1 tumor-bearing mice. K Body weight of 4T1 tumor-bearing mice with different treatments